Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Japan Approves Mounjaro, Tezspire, Fintepla, Label Expansions for Rinvoq/Skyrizi, Keytruda, and More
September 27, 2022
- MHLW’s Healthcare DX Promotion Team Holds 1st Meeting, Sets Up 2 Task Forces
September 27, 2022
- Keytruda Gets Label Update to Add Adjuvant Data for Melanoma
September 27, 2022
- Discussions on FY2023 Drug Price Revision Method to Be Held by Chuikyo: Minister
September 26, 2022
- Cost Rates of Drugs in Japan Worsen on Inflation, Weaker Yen: FPMAJ Survey
September 26, 2022
- Japan, US, European Trade Groups Eye Introduction of “Official Margins” in Price Revision Review
September 26, 2022
- Academic Experts Throw Candid Questions on Industry Structure, Pricing: Hearing
September 26, 2022
- Japan Generic Industry Prods Govt to Raise Drug Prices to Ensure Stable Supply
September 26, 2022
- Revamped Expert Panel Holds Industry Hearing, Discussions Center on Drug Price Gap
September 26, 2022
- Expand Range of Essential Drugs, Limit Coverage of Off-Year Re-Pricing: FPMAJ Member Associations
September 26, 2022
- MHLW Panel OKs 65 More Health Damage Claims for COVID-19 Vaccines
September 26, 2022
- Enhertu, BMS’s Luspatercept Grab Orphan Designation
September 22, 2022
- Japan Healthcare Spending Logs 44.2 Trillion Yen in FY2021, Up 4.6% on Post-Pandemic Rebound
September 21, 2022
- LDP OKs Draft Bill to Amend Infectious Disease Act to Enable Requests for Vaccine Production Boost in Emergencies
September 21, 2022
- 2 Years after Full Rollout, Sakigake System Shows Tepid Uptake as Industry Sees Poor Incentives
September 21, 2022
- MHLW Retools New Expert Panel, Industry Hearing Set for Sept. 22
September 21, 2022
- MHLW Eyes Diet Submission of Bill to Amend Cannabis Control Act Next Year: Official
September 20, 2022
- Japan Detects 14 More Probable Cases of Pediatric Hepatitis
September 20, 2022
- Japan OKs Additional Indications for 12 Fertility Treatments
September 20, 2022
- Moderna in Talks with Govt on Building Vaccine Plant in Japan: CEO
September 16, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…